Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis
Ahead of a critical meeting with an FDA committee, FibroGen Inc. stock tumbled more than 30% after hours on a fresh look at data around the safety of the San Francisco company's drug to treat anemia in chronic kidney disease patients. FibroGen officials said they continue to be confident in the risk-benefit profile of its drug, called roxadustat. Investors were not as optimistic: FibroGen stock (NASDAQ: FGEN) fell from a Tuesday high of $35.63 per share to $34.64 — off 2.8% on the day — then… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2021 Category: Biotechnology Source Type: news

Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis
Ahead of a critical meeting with an FDA committee, FibroGen Inc. stock tumbled more than 30% after hours on a fresh look at data around the safety of the San Francisco company's drug to treat anemia in chronic kidney disease patients. FibroGen officials said they continue to be confident in the risk-benefit profile of its drug, called roxadustat. Investors were not as optimistic: FibroGen stock (NASDAQ: FGEN) fell from a Tuesday high of $35.63 per share to $34.64 — off 2.8% on the day — then… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2021 Category: American Health Source Type: news

Meet 7 Health Workers Who Are Changing the Way We Approach Global Health Beyond the Pandemic
By The Editorial Team, IntraHealth InternationalApril 06, 2021Health workers know better than anyone what they need to be safe on the job. They know what it takes to be prepared for coronavirus cases as they come in the door. To end the COVID-19 pandemic, prevent future disease outbreaks, and to keep essential services running and available for their communities.During World Health Worker Week 2021, we’re amplifying their voices and recommendations on how we can better support and protect health workers—now and for the long haul.Meet seven health workers and leaders who are telling us what’s essential t...
Source: IntraHealth International - April 6, 2021 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 World Health Worker Week Health Workers Source Type: news

New Real-World Observational Analysis of UPTRAVI ® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
SOUTH SAN FRANCISCO, CA – April 6, 2021 – Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with UPTRAVI® (selexipag) either maintained (56%) or reduced (20%) their one-year mortality risk score. The SPHERE results were published in the April issue of the Journal of Heart and Lung Transplantation (JHLT). SPHERE is an ongoing real-world, observational, user registry using two different risk assessment methods that describes the clinical characte...
Source: Johnson and Johnson - April 6, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced that it has submitted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 30, 2021 Category: Drugs & Pharmacology Source Type: news

Vitamin B12 deficiency: White spots on your forearms is a lesser-known sign of low levels
VITAMIN B12 aids the body in essential ways yet some people struggle to absorb the vitamin due to an underlying condition called pernicious anaemia. This can raise one's risk of developing B12 deficiency. Seeing these spots on your forearms could mean your diet needs to change or supplements are needed. (Source: Daily Express - Health)
Source: Daily Express - Health - March 25, 2021 Category: Consumer Health News Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Sickle Cell Treatment Not Linked to Cancer, Researchers Say
Trials of experimental gene therapy for sickle cell disease were halted when patients developed worrying illnesses. (Source: NYT Health)
Source: NYT Health - March 10, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Genetics and Heredity Leukemia Clinical Trials DNA (Deoxyribonucleic Acid) Sickle Cell Anemia Bluebird Bio Inc Boston Children ' s Hospital Gene Therapy Source Type: news

Vitamin B12 deficiency: Six signs indicating you may be at risk of pernicious anaemia
VITAMIN B12 deficiency can produce changes to your physical and mental health. If you notice any of these six signs, it could indicate pernicious anaemia. (Source: Daily Express - Health)
Source: Daily Express - Health - March 8, 2021 Category: Consumer Health News Source Type: news

Vitamin B12 deficiency: Dr warns of 'irreversible' damage if warning signs are ignored
A VITAMIN B12 deficiency gravely impacts the body's ability to produce fully functioning red blood cells. As a consequence, megaloblastic anaemia develops and, left untreated over time, complications can occur. (Source: Daily Express - Health)
Source: Daily Express - Health - February 27, 2021 Category: Consumer Health News Source Type: news

Anti-aging biotech's first clinical trial aims to breathe new life into old blood
The East Bay company believes that boosting levels of hemoglobin by inhibiting a certain enzyme could treat unexplainable anemia in people over 65. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 25, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Liberia: LRC Receives U.S.$17.8 Million USAID Grant to Scale Up Health Services in Liberia
[FrontPageAfrica] Monrovia -- IRC Liberia has received a $17.8 million grant from USAID; the United States Agency for International Development to support the government of Liberia's National Community Health Program. Approximately 29% of the Liberian population, and 60% of the rural population live more than 5km from a health facility. With a host of health challenges in the area including high incidence of Malaria, anemia and a lack of reproductive health services, this USAID funded program will enable IRC to support the Liberian Min (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 25, 2021 Category: African Health Source Type: news

Researchers Halt Trials of Promising Sickle Cell Treatment
Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible. (Source: NYT Health)
Source: NYT Health - February 23, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Genetic Engineering Leukemia Bluebird Bio Inc Bone Marrow Clinical Trials DNA (Deoxyribonucleic Acid) Drugs (Pharmaceuticals) National Heart, Lung and Blood Institute Busulfan Black People Source Type: news

Researchers Halt Trial of Promising Sickle Cell Treatment
Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible. (Source: NYT Health)
Source: NYT Health - February 22, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Leukemia Bone Marrow Genetic Engineering Clinical Trials Bluebird Bio Inc Williams, David II DNA (Deoxyribonucleic Acid) National Heart, Lung and Blood Institute Busulfan Drugs (Pharmaceuticals) Source Type: news

After the Nobel, what next for Crispr  gene-editing therapies?
Hailed as the ‘molecular scissors’ that will allow us to rewrite our genes, the DNA tool is being trialled in treatments for everything from sickle-cell anaemia to cancerWhen last year ’s Nobel prize for chemistry was awarded tobiochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier for their work in developing the technique of gene editing known as Crispr-Cas9 (pronounced “crisper”), headlines hailed their discovery as “molecular scissors” that would allow us to “rewrite the book of life” – with all the complicated ethical questions that ability rais...
Source: Guardian Unlimited Science - February 21, 2021 Category: Science Authors: Philip Ball Tags: Gene editing Medical research Genetics Biology Science Cancer Huntington's disease Sickle cell disease Source Type: news

Shares plummet as bluebird bio suspends trials of sickle-cell anemia drug
Shares of bluebird bio hit their lowest value in more than six years after the Cambridge-based company suspended two trials of its gene therapy for sickle-cell anemia due to fears of serious side effects. Bluebird announced that it has temporarily suspended both an early-stage and a late-stage trial of bb1111 after it learned that blood cancer has been diagnosed in two former trial subjects. One patient who was treated with bb1111 “more than five years ago” was diagnosed with acute myeloid leuk emia,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 16, 2021 Category: Health Management Authors: Don Seiffert Source Type: news

Vitamin B12 deficiency: Irritability could be a sign of anaemia - what is that?
VITAMIN B12 deficiency anaemia can be a tiresome condition. As red blood cells struggle to form into the correct shape, oxygen fails to be delivered around the body, causing fatigue. (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2021 Category: Consumer Health News Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Foods Are Good and Bad for Your Diet if You Have Anemia?
Title: What Foods Are Good and Bad for Your Diet if You Have Anemia?Category: Diseases and ConditionsCreated: 2/5/2021 12:00:00 AMLast Editorial Review: 2/5/2021 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - February 5, 2021 Category: Anesthesiology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Late MI and Autoimmune Hemolytic Anemia in a COVID-19 Patient Late MI and Autoimmune Hemolytic Anemia in a COVID-19 Patient
Was this patient's autoimmune hemolytic anemia and myocardial infarction precipitated by concomitant COVID-19 infection?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Genome-editing tool TALEN outperforms CRISPR-Cas9 in tightly packed DNA
(University of Illinois at Urbana-Champaign, News Bureau) Researchers used single-molecule imaging to compare the genome-editing tools CRISPR-Cas9 and TALEN. Their experiments revealed that TALEN is up to five times more efficient than CRISPR-Cas9 in parts of the genome, called heterochromatin, that are densely packed. Fragile X syndrome, sickle cell anemia, beta-thalassemia and other diseases are the result of genetic defects in the heterochromatin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2021 Category: International Medicine & Public Health Source Type: news

How Do You Treat Anemia in Children?
Title: How Do You Treat Anemia in Children?Category: Diseases and ConditionsCreated: 1/25/2021 12:00:00 AMLast Editorial Review: 1/25/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - January 25, 2021 Category: Pediatrics Source Type: news

What Causes Lethargy?
Discussion Lethargy is a common word used to describe a person who is drowsy, sluggish, listless and apathetic. Concentration may be difficult and they may have problems doing simple tasks. Many people actual mean fatigue or lassitude or being more tired when they use the word. In medical terms, lethargy is usually used to describe patients who have some type of excessive tiredness and usually have mental status changes with decreased alertness or arousal. Patients and health care providers both usually qualify the term and give more description to better communicate what is implied when using the term. This is true of man...
Source: PediatricEducation.org - January 25, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Vitamin B12 deficiency symptoms: Feeling your own heartbeat may be a sign
VITAMIN B12 deficiency is otherwise known as folate deficiency anaemia, and symptoms of the condition can slowly creep up on you. Are you being affected? (Source: Daily Express - Health)
Source: Daily Express - Health - January 24, 2021 Category: Consumer Health News Source Type: news

$3.25 million in grants to stand up to cancer will improve head and neck cancer treatments
(Stand Up To Cancer) Stand Up To Cancer ® has received $3.25 million in grants from four national nonprofits to fund research to find new treatments for head and neck cancers, which are newly diagnosed in about 65,000 Americans every year. The grants include contributions of $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance each provided $125,000. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Higher Hb Threshold for Transfusion Not Better for Preemies
WEDNESDAY, Jan. 13, 2021 -- Use of a higher hemoglobin transfusion threshold does not lower the risk for death or neurodevelopmental impairment at 22 to 26 months of age among extremely low-birth-weight infants with anemia, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2021 Category: Pharmaceuticals Source Type: news

Toxins In Marijuana Smoke May Be Harmful To Health, Dana-Farber Study Finds
(CNN) — Smoking weed may expose you to the same type of toxic chemicals found in tobacco smoke, a new study finds. People who only smoked marijuana had higher blood and urine levels of several smoke-related toxins such as naphthalene, acrylamide and acrylonitrile than nonsmokers, according to the study published Monday in the journal EClinicalMedicine. Naphthalene is associated with anemia, liver and neurological damage, while acrylamide and acrylonitrile have been associated with cancer and other health issues. “Marijuana use is on the rise in the United States with a growing number of states legalizing it for...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 11, 2021 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Dana Farber Cancer Institute Marijuana Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Ferric derisomaltose saves costs in treatment of iron-deficiency anaemia in IBD
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2021 Category: Drugs & Pharmacology Source Type: news

Higher Red-Cell Transfusion Limit for Preemies Offers No Survival, Developmental Benefit Higher Red-Cell Transfusion Limit for Preemies Offers No Survival, Developmental Benefit
Aggressive use of red-cell transfusion for extremely-low-birth-weight newborns with anemia does not improve survival and fails to stem neurodevelopmental impairment by age 2, a new study finds.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2020 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Study: Preterm babies don't benefit from higher red blood cell transfusions
Very low birth weight babies born with anemia don't need transfusions with a high number of red blood cells to avoid complications including developmental delays, cerebral palsy, or hearing and vision loss, a study found (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 30, 2020 Category: Consumer Health News Source Type: news

Vitamin B9 deficiency symptoms: Irritability could be a sign of folate deficiency anaemia
A VITAMIN B9 deficiency can lead to folate deficiency anaemia, whereby the body is unable to create a sufficient number of red blood cells. This results in various side effects, including irritability. (Source: Daily Express - Health)
Source: Daily Express - Health - December 30, 2020 Category: Consumer Health News Source Type: news

What Causes Anemic Hypoxia?
Title: What Causes Anemic Hypoxia?Category: Diseases and ConditionsCreated: 12/22/2020 12:00:00 AMLast Editorial Review: 12/22/2020 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - December 22, 2020 Category: Respiratory Medicine Source Type: news

After nearly $1 billion and 27 years, S.F. biotech now must wait another 90 days for 1st FDA decision
A Food and Drug Administration decision on whether to approve a drug from FibroGen Inc. to treat anemia in chronic kidney disease patients was delayed Friday for 90 days. San Francisco-based FibroGen (NASDAQ: FGEN) and partner AstraZeneca plc (NASDAQ: AZN) expected a decision by Sunday, but the FDA said it required additional analyses of existing clinical trial results for the drug, called roxadustat. The agency moved the decision date to March 20. FibroGen CEO En rique Conterno said in a statement… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Aren ’t We Missing Food Security Experts in the Incoming President-Elect Biden-Kamala Harris Administration?
We never imagined that we would witness food insecurity being an issue in developed countries such as the US. Credit: Stephen Leahy/IPS.By Esther Ngumbi and Ifeanyi NsoforURBANA, Illinois / ABUJA, Dec 17 2020 (IPS) Food insecurity across the U.S. continues to be on the rise because of the effects of COVID-19. According to Feeding America, over 50 million Americans will experience food insecurity, including 17 million children.  We both grew up in countries referred to as “developing countries,” Ifeanyi in Nigeria and Esther in Kenya. At the time, we never imagined that we would witness food insecurity...
Source: IPS Inter Press Service - Health - December 17, 2020 Category: International Medicine & Public Health Authors: Esther Ngumbi and Ifeanyi Nsofor Tags: Food & Agriculture Headlines Health Source Type: news

Uganda: Sickle Cell Warriors Receive Phones With Health App for Quick Treatment During Tough Covid-19 Times
[Monitor] At least 10,000 people living with sickle cell anemia, are each to be availed with a smart phone that they can make use of to get treatment from a doctor given the ongoing restrictions caused by Covid-19. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 15, 2020 Category: African Health Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hair loss treatment: Iron supplements may promote hair growth
HAIR LOSS can be a sign of an underlying medical condition that, with treatment, can restore hair growth. If you have iron deficiency anaemia, taking iron supplements may help. How do you know if you have this? (Source: Daily Express - Health)
Source: Daily Express - Health - December 5, 2020 Category: Consumer Health News Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Integrated anemia-SCD test demonstrates accurate results in study at 2020 ASH meeting
(Whitecoat Strategies, LLC) Researchers from Case Western Reserve University presented research today in which Hemex Health's affordable Gazelle platform diagnostic technology successfully tested 46 patients with 100% sensitivity and over 92.3% specificity for anemia and with 100% accuracy for hemoglobin variants. The preliminary study included blood samples collected from Cleveland-area patients studied for anemia and sickle cell disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 5, 2020 Category: Infectious Diseases Source Type: news

Iron deficiency can be managed better
(Walter and Eliza Hall Institute) Publishing in The Lancet, Australian and European researchers have released updated, evidence-based guidance for managing iron deficiency, a serious worldwide health problem. Iron deficiency is a major cause of anaemia, a lack of oxygen-carrying red blood cells or haemoglobin, which is experienced by two billion people worldwide, and can have serious long-term health consequences. Implementing the best practice diagnosing and managing iron deficiency would lead to significant long-term health benefits. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 4, 2020 Category: Biology Source Type: news

Can AI software drive CT lung screening rates higher?
Can software based on artificial intelligence improve the anemic rates of CT...Read more on AuntMinnie.comRelated Reading: RapidAI touts rapid growth in AI use RapidAI teams with Penumbra to develop tools for PE Minnies winners for 2020 shaped by COVID-19 pandemic Meet the Minnies 2020 finalists Meet the Minnies 2020 semifinal candidates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 1, 2020 Category: Radiology Source Type: news

Column: For a man long afflicted with an illness made riskier by COVID-19, hope for the holidays
Black people are the overwhelming victims of sickle cell anemia. An experimental gene therapy being tested on Evie Junior, 27, gives him reason to feel positive. (Source: L.A. Times - Health)
Source: L.A. Times - Health - November 29, 2020 Category: Consumer Health News Authors: Sandy Banks Source Type: news

Column: For a man long afflicted with an illness made riskier by COVID-19, hope for the holidays
Black people are the overwhelming victims of sickle cell anemia. An experimental gene therapy being tested on Evie Junior, 27, gives him reason to feel positive. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - November 29, 2020 Category: Science Authors: Sandy Banks Source Type: news

Need to intensify efforts to address all causes of anemia: Healthcare experts
According to the Comprehensive National Nutrition Survey, approximately half of the women of the reproductive age group are anemic and 41 per cent of preschoolers, 24 per cent of school-age children and 28 per cent of adolescents are reported to be anemic. (Source: The Economic Times)
Source: The Economic Times - November 29, 2020 Category: Consumer Health News Source Type: news